Cigna Drops Coverage of Mylan's EpiPen for Cheaper Generic
January 12 2017 - 12:49PM
Dow Jones News
By Anne Steele
A top U.S. health insurer has dropped its coverage of Mylan NV's
EpiPen and switched to its generic alternative, following public
outrage over sharp price increases for the lifesaving drug.
Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan's
half-priced generic version, according to a document outlining
Cigna's pharmacy benefit manager's prescription drug changes for
2017.
Mylan's generic version of the epinephrine auto-injector pen was
launched in December and has the same drug formulation and device
functionality as the original -- a product that has been on the
market for nearly 30 years -- and is administered in the same
way.
Mylan took heat this summer for its price increases on EpiPen --
the list price since 2007 had climbed nearly 550% from about $94,
according to data from Truven Health Analytics -- and in August
said it would begin selling the generic product for a price of $300
for two injection pens, compared with a list price of about $609
for its branded EpiPen product.
A Mylan spokeswoman said Cigna's move was expected. "These
changes were anticipated and are why we anticipate successful
generic utilization," she said.
A spokesman for Express Scripts Holding Co., the largest
administrator of prescription-drug programs for insurers, on
Thursday said EpiPen continues to be on its list of preferred
drugs, and said it is evaluating the authorized generic.
Shares of Mylan declined 2.4% to $36.40 in morning trading.
Write to Anne Steele at Anne.Steele@wsj.com
(END) Dow Jones Newswires
January 12, 2017 12:34 ET (17:34 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024